The Council of Better Business Bureaus appeals board agrees that testing does not support claims that Colgate Sensitive Pro-Relief is “faster” and “better” than GlaxoSmithKline's Sensodyne. Colgate argued its studies were sufficient, having incorporated industry-standard methodology accepted by FDA and the ADA.
The National Advertising Review Board upholds recommendations by its investigative unit that Colgate-Palmolive discontinue certain superiority claims for Colgate Sensitive Pro-Relief toothpaste.
In a decision released Sept. 17, NARB upheld the National Advertising Division’s opinion that claims that Pro-Relief is “faster” and “better” than GlaxoSmithKline's Sensodyne were not supported by testing.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.
